BioRestorative Therapies (BRTX) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 14, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-37603
Entity Registrant Name	BIORESTORATIVE THERAPIES, INC.
Entity Central Index Key	0001505497
Entity Tax Identification Number	91-1835664
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	40 Marcus Drive
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	(631)
Local Phone Number	760-8100
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	BRTX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		3,673,629

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 6,573,111	$ 21,026,727
Investments held in marketable securities	9,913,667
Accounts receivable	45,000	5,000
Prepaid expenses and other current assets	356,046	436,181
Total Current Assets	16,887,824	21,467,908
Property and equipment, net	231,324	37,993
Right of use asset	270,772	357,805
Intangible assets, net	530,298	589,740
Total Assets	17,920,218	22,453,446
Current Liabilities:
Accounts payable	468,501	50,827
Accrued expenses and other current liabilities	114,647	134,970
Lease liability, current portion	134,031	119,055
PPP loan payable, current portion		58,970
Total Current Liabilities	717,179	363,822
Lease liability, net of current portion	198,724	301,645
PPP loan payable, net of current portion		191,030
Total Liabilities	915,903	856,497
Commitments (Note 7)
Stockholders’ Equity
Common stock, $0.0001 par value; Authorized, 75,000,000 shares; 3,646,450 and 3,520,391 issued and outstanding at September 30, 2022 and December 31, 2021, respectively	365	353
Additional paid in capital	165,281,862	155,727,292
Accumulated deficit	(148,293,344)	(134,146,128)
Total Stockholders’ Equity	17,004,315	21,596,949
Total Liabilities and Stockholders’ Equity	17,920,218	22,453,446
Series A Convertible Preferred Stock [Member]
Stockholders’ Equity
Preferred stock, value		15,432
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity
Preferred stock, value	$ 15,432

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	3,646,450	3,520,391
Common stock, shares outstanding	3,646,450	3,520,391
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,543,158	1,543,158
Preferred stock, shares issued	0	1,543,158
Preferred stock, shares outstanding	0	1,543,158
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,543,158	1,543,158
Preferred stock, shares issued	1,543,158	0
Preferred stock, shares outstanding	1,543,158	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenues	$ 29,000	$ 8,000	$ 116,100	$ 41,000
Operating expenses:
Research and development	989,170	237,410	2,839,731	563,562
General and administrative	3,649,530	3,459,277	11,568,490	21,776,044
Total operating expenses	4,638,700	3,696,687	14,408,221	22,339,606
Loss from operations	(4,609,700)	(3,688,687)	(14,292,121)	(22,298,606)
Other (income) expense:
Interest expense	28,841	495,545	104,465	1,601,551
Gain on PPP loan forgiveness			(250,000)
Grant income			(16,654)
Other expense	17,284		17,284
Total other (income) expense	46,125	495,545	(144,905)	1,601,551
Net loss	$ (4,655,825)	$ (4,184,232)	$ (14,147,216)	$ (23,900,157)
Net Loss Per Share - Basic and Diluted	$ (1.28)	$ (4.99)	$ (3.93)	$ (30.31)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	3,642,215	838,689	3,602,979	788,564

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Convertible Preferred Stock [Member] Preferred Stock [Member]	Series B Convertible Preferred Stock [Member] Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020			$ 72	$ 88,511,269	$ (89,842,833)	$ (1,331,492)
Balance, shares at Dec. 31, 2020			715,544
Balance, shares at Dec. 31, 2020			(715,544)
- restricted share units				179,098		179,098
- options				13,897,669		13,897,669
Net loss					(15,653,330)	(15,653,330)
Shares issued in exchange for notes payable and accrued interest				213,673		213,673
Shares issued in exchange for notes payable and accrued interest, shares			4,852
Shares issued in cashless exercise of warrants			$ 7	(7)
Shares issued in cashless exercise of warrants, shares			73,582
Ending balance, value at Mar. 31, 2021			$ 79	102,801,702	(105,496,163)	(2,694,382)
Ending balance, shares at Mar. 31, 2021			793,978
Beginning balance, value at Dec. 31, 2020			$ 72	88,511,269	(89,842,833)	(1,331,492)
Balance, shares at Dec. 31, 2020			715,544
Balance, shares at Dec. 31, 2020			(715,544)
Net loss						(23,900,157)
Ending balance, value at Sep. 30, 2021			$ 87	108,863,599	(113,742,990)	(4,879,304)
Ending balance, shares at Sep. 30, 2021			872,195
Beginning balance, value at Mar. 31, 2021			$ 79	102,801,702	(105,496,163)	(2,694,382)
Balance, shares at Mar. 31, 2021			793,978
Balance, shares at Mar. 31, 2021			(793,978)
- restricted share units				1,164,135		1,164,135
- options				1,762,329		1,762,329
Net loss					(4,062,595)	(4,062,595)
Shares issued in exchange for notes payable and accrued interest				103,703		103,703
Shares issued in exchange for notes payable and accrued interest, shares			3,217
Shares issued in cashless exercise of warrants			$ 4	(82,135)		(82,131)
Shares issued in cashless exercise of warrants, shares			39,750
Ending balance, value at Jun. 30, 2021			$ 83	105,749,734	(109,558,758)	(3,808,941)
Ending balance, shares at Jun. 30, 2021			836,945
Balance, shares at Jun. 30, 2021			(836,945)
- restricted share units				1,164,135		1,164,135
- options				1,762,330		1,762,330
Net loss					(4,184,232)	(4,184,232)
Shares issued in cashless exercise of warrants			$ 4	(4)
Shares issued in cashless exercise of warrants, shares			34,500
Shares issued in litigation settlement				21,000		21,000
Shares issued in litigation settlement , shares			750
Fair market value of beneficial conversion feature and warrants issued with convertible notes payable instruments				166,404		166,404
Ending balance, value at Sep. 30, 2021			$ 87	108,863,599	(113,742,990)	(4,879,304)
Ending balance, shares at Sep. 30, 2021			872,195
Beginning balance, value at Dec. 31, 2021	$ 15,432		$ 353	155,727,292	(134,146,128)	21,596,949
Balance, shares at Dec. 31, 2021	1,543,158		3,520,391
Balance, shares at Dec. 31, 2021	(1,543,158)		(3,520,391)
- restricted share units			$ 10	1,164,125		1,164,135
Restricted share units, shares			97,828
- options				2,138,949		2,138,949
- common stock			$ 1	72,818		72,819
Common stock, shares			13,500
Net loss					(4,816,150)	(4,816,150)
Ending balance, value at Mar. 31, 2022	$ 15,432		$ 364	159,103,184	(138,962,278)	20,156,702
Ending balance, shares at Mar. 31, 2022	1,543,158		3,631,719
Beginning balance, value at Dec. 31, 2021	$ 15,432		$ 353	155,727,292	(134,146,128)	21,596,949
Balance, shares at Dec. 31, 2021	1,543,158		3,520,391
Balance, shares at Dec. 31, 2021	(1,543,158)		(3,520,391)
Net loss						(14,147,216)
Ending balance, value at Sep. 30, 2022		$ 15,432	$ 365	165,281,862	(148,293,344)	17,004,315
Ending balance, shares at Sep. 30, 2022		1,543,158	3,646,450
Beginning balance, value at Mar. 31, 2022	$ 15,432		$ 364	159,103,184	(138,962,278)	20,156,702
Balance, shares at Mar. 31, 2022	1,543,158		3,631,719
Balance, shares at Mar. 31, 2022	(1,543,158)		(3,631,719)
- restricted share units			$ 1	1,190,349		1,190,350
Restricted share units, shares			6,220
- options				1,865,297		1,865,297
- common stock				48,504		48,504
Common stock, shares			5,770
Net loss					(4,675,241)	(4,675,241)
Ending balance, value at Jun. 30, 2022	$ 15,432		$ 365	162,207,334	(143,637,519)	18,585,612
Ending balance, shares at Jun. 30, 2022	1,543,158		3,643,709
Balance, shares at Jun. 30, 2022	(1,543,158)		(3,643,709)
Net loss						(4,655,825)
Ending balance, value at Sep. 30, 2022		$ 15,432	$ 365	165,281,862	(148,293,344)	17,004,315
Ending balance, shares at Sep. 30, 2022		1,543,158	3,646,450
Beginning balance, value at Sep. 07, 2022	$ (15,432)	$ 15,432
Balance, shares at Sep. 07, 2022	1,543,158	1,543,158
Balance, shares at Sep. 07, 2022	(1,543,158)	(1,543,158)
- restricted share units				1,209,231		1,209,231
Restricted share units, shares			6,218
- options				1,865,297		1,865,297
- common stock
Common stock, shares			(3,477)
Net loss					(4,655,825)	(4,655,825)
Ending balance, value at Sep. 30, 2022		$ 15,432	$ 365	$ 165,281,862	$ (148,293,344)	$ 17,004,315
Ending balance, shares at Sep. 30, 2022		1,543,158	3,646,450

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net Loss	$ (14,147,216)	$ (23,900,157)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		1,068,498
Unrealized loss on marketable securities	19,895
Depreciation and amortization	88,751	67,612
Stock-based compensation - options	5,869,543	17,422,328
Stock-based compensation - common stock	121,323
Stock-based compensation - RSUs	3,563,716	2,507,368
Shares issued in settlement of litigation		21,000
Gain on PPP loan forgiveness	(250,000)
Non-cash lease expense	87,033	87,033
Changes in operating assets and liabilities:
Accounts receivable	(40,000)	9,000
Prepaid assets and other current assets	80,135	73,451
Accounts payable	417,674	5,707
Accrued expenses and other current liabilities	(20,321)	528,015
Lease liability	(87,945)	(74,749)
Net cash used in operating activities	(4,297,412)	(2,184,894)
Cash flows from investing activities:
Purchase of marketable securities	(9,933,562)
Purchases of equipment	(222,642)
Net cash used in investing activities	(10,156,204)
Cash flows from financing activities:
Proceeds from PPP Loan		250,000
Net cash provided by financing activities		250,000
Net decrease in cash and cash equivalents	(14,453,616)	(1,934,894)
Cash and cash equivalents - beginning of period	21,026,727	3,064,610
Cash and cash equivalents - end of period	6,573,111	1,129,716
Non-cash investing and financing activities:
Shares issued in exchange for notes payable and accrued interest		317,376
Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount		166,404
Accrued DIP expenses exchanged for convertible notes		$ 698,901

NATURE OF THE ORGANIZATION, LIQ

NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS	NOTE 1 – NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS Corporate History BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company”. On October 27, 2021, the Company effected a 1-for-4,000 300,000,000,000 75,000,000 On November 9, 2021, the Company completed a $ 23,000,000 2,300,000 2,645,000 Nature of the Business BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com. BRT is currently developing a Disc/Spine Program referred to as “brtxDISC”. Its lead cell therapy candidate, BRTX-100 Liquidity The accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the nine months ended September 30, 2022, the Company had a net loss of $ 14.1 million (of which, $ 9.6 million was attributable to non-cash stock-based compensation) and negative cash flows from operations of $ 4.3 million. The Company’s operating activities consume the majority of its cash resources. The Company anticipates that it will continue to incur net losses as it executes its development plans for 2022 and beyond, as well as other potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand and additional infusions of cash from equity and debt financing. Based on cash on hand as of September 30, 2022, the Company believes it has sufficient cash to fund operations for the twelve months subsequent to the filing date. Current funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial information as of and for the three and nine months ended September 30, 2022 and 2021 has been prepared in accordance with GAAP for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position at such dates and the operating results and cash flows for such periods. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (the “SEC”). These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2022. Prior Period Reclassifications Certain prior period amounts have been reclassified for consistency with current period presentation. These reclassifications had no effect on the condensed consolidated statements of operations or cash flows. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated upon consolidation. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the accompanying unaudited condensed consolidated financial statements. Significant estimates include the carrying value of intangible assets, deferred tax asset and valuation allowance, and assumptions used in the Black-Scholes option pricing model, such as expected volatility, risk-free interest rate, and expected dividend rate. Revenue The Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012 and amended in November 2015. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures, and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company’s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s contracts have a single performance obligation with a fixed determinable contract value. The Company’s performance obligation is satisfied upon the transfer of risk of loss to the customer. All sales have fixed pricing and there are currently no variable components included in the Company’s revenue. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the three months ended September 30, 2022 and 2021, the Company recognized $ 29,000 8,000 116,100 41,000 Contract Modifications There were no contract modifications during the three and nine months ended September 30, 2022. Contract modifications are not routine in the performance of the Company’s contracts. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through, as well as maintaining cash balances with, major financial institutions. As of September 30, 2022, the Company had cash and cash equivalents totaling $ 16.5 million. Fair Value Measurements As defined in ASC 820, Fair Value Measurements and Disclosures Level 1: Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2: Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3: Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed methodologies that result in management’s best estimate of fair value. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2022, and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE RECURRING BASIS Fair value measurements at reporting date using: Description Fair Value Quoted Significant other Significant Assets: Cash equivalents as of September 30, 2022 $ 4,898,305 $ 4,898,305 $ - $ - Marketable securities as of September 30, 2022 $ 9,913,667 $ 9,913,667 $ - $ - Marketable securities as of December 31, 2021 $ - $ - $ - $ - Net Loss per Common Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. All vested outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options, warrants, and restricted stock units (“RSUs”) are calculated using the treasury stock method. All outstanding convertible notes are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants, RSUs and convertible notes have been excluded from the Company’s computation of net loss per common share for the three and nine months ended September 30, 2022 and 2021. The following table summarizes the securities that were excluded from the diluted loss per share calculation: SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES Three Months Ended September 30, 2022 2021 Options 864,609 588,048 Warrants 4,739,723 3,704,997 Unvested RSUs 208,086 293,479 Convertible notes – common stock (1) - 697,582 Total 5,812,418 5,284,121 Nine Months Ended September 30, 2022 2021 Options 864,609 588,048 Warrants 4,739,723 3,704,997 Unvested RSUs 208,086 293,479 Convertible notes – common stock (1) - 697,582 Total 5,812,418 5,284,121 (1) As of September 30, 2021, all of the convertible notes had variable conversion prices and the shares issuable were estimated based on the market conditions. Pursuant to the note agreements, there were 12,876,004 Stock-based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation For stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to Accounting Standards Update (“ASU”) 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are consistent with the process for valuing employee stock options noted above. Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment. The Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company routinely evaluates the realizability of deferred tax assets by assessing the likelihood that deferred tax assets will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, historical results are considered along with certain assumptions related to future earnings. As of September 30, 2022 and December 31, 2021, the Company had a full valuation allowance applied against its deferred tax assets. From time to time the Company may recognize an income tax benefit, in its consolidated statements of operations, related to uncertain tax positions taken. For uncertain tax positions that are “more likely than not” to sustain an income tax audit, the Company may record an allowance against certain deferred tax assets related to these positions. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the unaudited condensed consolidated statements of operations. Research and Development Expenses Research and development expenses are expensed as incurred and recorded as a component of operating expenses in the Company’s condensed consolidated statements of operations.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 3 – INTANGIBLE ASSETS The Company is a party to a license agreement with the SCTC (as amended) (the “SCTC Agreement”). Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain method for culturing cells and a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body). Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology (subject to the SCTC’s compliance with its obligations under the SCTC Agreement). The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights may currently be non-exclusive. The Company and the SCTC are currently negotiating the terms of an agreement confirming the exclusive nature of the license. No assurance can be given in this regard. In February 2017, the Company received authorization from the Food and Drug Administration (the “FDA”) to proceed with a Phase 2 clinical trial. The Company has commenced such clinical trial. In March 2022, a United States patent relating to the Company’s BRTX-100 clinical program was issued. The patent along with the license agreement gave rise to definite lived intangible assets. The below table details the activity related to those intangible assets from January 1, 2021 through September 30, 2022: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS Patents and Licenses Accumulated Total Balance as of January 1, 2021 $ 3,676 $ 1,301,500 $ (640,908 ) $ 664,268 Amortization expense - - (74,528 ) (74,528 ) Balance as of December 31, 2021 3,676 1,301,500 (715,436 ) 589,740 Amortization expense - - (59,442 ) (59,442 ) Balance as of September 30, 2022 $ 3,676 $ 1,301,500 $ (774,878 ) $ 530,298 Weighted average remaining amortization period as of September 30, 2022 (in years) - 7.18 Accumulated amortization of intangible assets consists of the following: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES Patents and Licenses Accumulated Balance as of January 1, 2021 $ 3,676 $ 637,232 $ 640,908 Amortization expense - 74,528 74,528 Balance as of December 31, 2021 3,676 711,760 715,436 Amortization expense - 59,442 59,442 Balance as of September 30, 2022 $ 3,676 $ 771,202 $ 774,878

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 4 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES September 30, December 31, Accrued payroll $ 26,250 $ 28,370 Accrued research and development expenses - 29,672 Accrued general and administrative expenses 88,397 76,928 Total accrued expenses $ 114,647 $ 134,970

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 5 – NOTES PAYABLE A summary of the notes payable activity during the nine months ended September 30, 2022 is presented below: SCHEDULE OF NOTES PAYABLE ACTIVITY PPP Loan Outstanding, January 1, 2022 $ 250,000 Issuances - Forgiveness (250,000 ) Outstanding, September 30, 2022 $ - On March 14, 2021, under the U.S. Small Business Administration’s Paycheck Protection Program (“PPP”), the Company entered into a note payable with a financial institution for $ 250,000 1 March 14, 2026 Pursuant to the note, principal and interest payments were deferred for ten months. At that time the Company was able to apply for loan forgiveness. At December 31, 2021, $ 250,000

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT) Series A Preferred Stock On November 8, 2021, in connection with the Company’s public offering, the Company’s Board of Directors adopted a resolution allowing for the authorization and issuance of 1,543,458 .01 0.001 1,543,158 Series B Preferred Stock Effective September 8, 2022, the Company issued 1,543,158 The terms of the Series B are substantially identical to those of the Series A, except that, among other things, the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as provided for the Series A On October 25, 2022, Auctus converted 25,000 25,000 10.00 1,518,158 Dividends Series B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible. Voting Rights Series B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law. The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled to vote more than 9.99 Conversion Optional Conversion - Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into one share of Common Stock based upon a conversion price of $ 10.00 9.99 Automatic Conversion – From time to time, in the event of that an event occurs, including adjustment due to merger, consolidation, etc., subdivision or combination of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the effect of reducing a Series B holder’s beneficial ownership of shares of common stock to less than 9.5 9.99 2021 Stock Incentive Plan On March 18, 2021, the Company’s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). Pursuant to the 2021 Plan, a total of 1,175,000 no Amendments to 2021 Stock Incentive Plan On December 10, 2021, subject to stockholder approval, the Company’s Board of Directors approved amendments to the 2021 Plan to increase the number of shares of Common Stock authorized to be issued from 1,175,000 to 2,500,000 and to clarify certain provisions of the 2021 Plan as to the authority of the Board of Directors and the Compensation Committee to make adjustments to, among other things, the exercise price of granted options. 838,549 shares of the Company’s common stock from $ 13.50 per share to $ 5.08 per share (the closing price of the Company’s common stock on the day immediately preceding the Compensation Committee determination), including the options held by the Company’s officers and directors as follows: (i) Lance Alstodt, the Company’s President, Chief Executive Officer and Chairman of the Board: 335,538 shares, (ii) Francisco Silva, the Company’s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal, the Company’s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company’s Vice President of Quality Assurance and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company’s directors: 25,236 shares; (vi) Patrick F. Williams, one of the Company’s directors: 10,490 shares; and (vii) David Rosa, one of the Company’s directors: 10,490 shares . On November 3, 2022, the Company’s stockholders approved the amendments to the 2021 Plan. As of September 30, 2022, options for the purchase of 864,609 318,356 2,500,000 5.08 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Warrant Activity Summary No warrants were granted or issued during the nine months ended September 30, 2022 and 2021. A summary of the warrant activity during the nine months ended September 30, 2022, is presented below: SCHEDULE OF WARRANT ACTIVITY Weighted Average Number of Exercise Warrants Price Outstanding, January 1, 2022 4,739,871 $ 11.78 Granted - - Exercised - - Expired (148 ) 16,099.00 Outstanding, September 30, 2022 4,739,723 $ 10.89 Exercisable, September 30, 2022 4,739,723 $ 10.89 Stock Options The Company grants stock options to certain employees which are recognized as compensation expense on a straight-line basis over the vesting term of the grants. Vesting terms are generally two years, and grants expire between five and ten years. For the three months ended September 30, 2022 and 2021, the Company recognized compensation expense related to stock option grants of $ 1.9 1.7 6.0 17.4 The Company granted options for the purchase of 25,000 4.88 0.09 The Company granted options for the purchase of 586,959 47.25 3.2 A summary of the stock option activity during the nine months ended September 30, 2022 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY Weighted Average Number of Exercise Options Price Outstanding, January 1, 2022 839,639 $ 18.73 Granted 25,000 4.92 Forfeited (30 ) 3,273.00 Outstanding, September 30, 2022 864,609 $ 18.73 Exercisable, September 30, 2022 532,045 $ 17.50 Restricted Stock Units Pursuant to the 2021 Plan, the Company grants RSUs to employees, consultants and non-employee directors (“Eligible Individuals”). The number, terms and conditions of the RSUs that are granted to Eligible Individuals are determined on an individual basis by the plan administrator. On the distribution date, the Company shall issue to the Eligible Individual one share of the Company’s common stock for each vested and nonforfeitable RSU. On March 18, 2022, the Company granted an aggregate of 24,876 4.21 A summary of the Company’s unvested RSUs as of September 30, 2022 is as follows: SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS Number of Shares Outstanding, January 1, 2022 293,480 Granted 24,876 Forfeited - Vested (110,270 ) Outstanding, September 30, 2022 208,086 There were 2,074 For the three months ended September 30, 2022 and 2021, the Company recognized compensation expense related to RSUs of $ 1.2 1.2 3.6 2.5 For the three months ended September 30, 2022 and 2021, the Company recognized compensation expense of $ 3.1 2.9 9.6 19.9 The Company’s unrecognized compensation expense was $ 10.8

COMMITMENTS

COMMITMENTS	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS	Note 7 - COMMITMENTS Clinical Services Agreement On December 20, 2021, the Company entered into a Master Clinical Services Agreement (the “Clinical Services Agreement”) with Professional Research Consulting, Inc. (“PRC”) pursuant to which PRC will provide trial management services related to the Company’s Phase 2 clinical trials. The Clinical Services Agreement has a 46 5,844,380 328,152 0.6 1.7 0.3

LEASES

LEASES	9 Months Ended
	Sep. 30, 2022
Leases
LEASES	Note 8 - LEASES The Company is a party to a lease for 6,800 The Melville Lease is scheduled to expire in December 2024 and provides for an annual base rental during the term, which commenced as of January 1, 2020, ranging between $ 153,748 173,060 2.25 When calculating the present value of lease liabilities for operating leases, the Company discounted the lease payments using its estimated incremental borrowing rate at the inception of the term. The weighted average incremental borrowing rate applied to the Melville Lease was 12 The following table presents net lease cost and other supplemental lease information: SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION Nine Months Nine Months Lease cost Operating lease cost (cost resulting from lease payments) $ 122,349 $ 118,779 Net lease cost $ 122,349 $ 118,779 Operating lease – operating cash flows (fixed payments) $ 122,349 $ 118,779 Operating lease – operating cash flows (liability reduction) $ 87,945 $ 74,749 Non-current leases – right of use assets $ 270,772 $ 386,816 Current liabilities – operating lease liabilities $ 134,031 $ 114,387 Non-current liabilities – operating lease liabilities $ 198,724 $ 332,755 Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of September 30, 2022: SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES Fiscal Year Operating Leases Remainder of 2022 $ 40,783 2023 168,028 2024 173,060 Total future minimum lease payments 381,871 Amount representing interest (49,116 ) Present value of net future minimum lease payments $ 332,755

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS On November 3, 2022, BioRestorative Therapies, Inc. held its Annual Meeting of Stockholders. At the Annual Meeting, the Company’s stockholders: (i) elected the nominees as the Class II directors, (ii) approved amendments to the Company’s 2021 Stock Incentive Plan, (iii) authorized the reincorporation of the Company from the State of Delaware to the State of Nevada, (iv) approved, on a non-binding advisory basis, the compensation of the Company’s executive officers, (v) recommended, on a non-binding advisory basis, that future advisory votes be held every three years with regard to the approval of the Company’s executive compensation, and (vi) ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial information as of and for the three and nine months ended September 30, 2022 and 2021 has been prepared in accordance with GAAP for interim financial information and with the instructions to Quarterly Report on Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, such financial information includes all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position at such dates and the operating results and cash flows for such periods. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (the “SEC”). These unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2022.
Prior Period Reclassifications	Prior Period Reclassifications Certain prior period amounts have been reclassified for consistency with current period presentation. These reclassifications had no effect on the condensed consolidated statements of operations or cash flows.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the accompanying unaudited condensed consolidated financial statements. Significant estimates include the carrying value of intangible assets, deferred tax asset and valuation allowance, and assumptions used in the Black-Scholes option pricing model, such as expected volatility, risk-free interest rate, and expected dividend rate.
Revenue	Revenue The Company derives all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012 and amended in November 2015. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures, and the Company has granted to the SCTC a sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company’s contracted transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s contracts have a single performance obligation with a fixed determinable contract value. The Company’s performance obligation is satisfied upon the transfer of risk of loss to the customer. All sales have fixed pricing and there are currently no variable components included in the Company’s revenue. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the three months ended September 30, 2022 and 2021, the Company recognized $ 29,000 8,000 116,100 41,000
Contract Modifications	Contract Modifications There were no contract modifications during the three and nine months ended September 30, 2022. Contract modifications are not routine in the performance of the Company’s contracts.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents held at financial institutions may at times exceed insured amounts. The Company believes it mitigates such risk by investing in or through, as well as maintaining cash balances with, major financial institutions. As of September 30, 2022, the Company had cash and cash equivalents totaling $ 16.5 million.
Fair Value Measurements	Fair Value Measurements As defined in ASC 820, Fair Value Measurements and Disclosures Level 1: Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2: Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3: Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed methodologies that result in management’s best estimate of fair value. The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2022, and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE RECURRING BASIS Fair value measurements at reporting date using: Description Fair Value Quoted Significant other Significant Assets: Cash equivalents as of September 30, 2022 $ 4,898,305 $ 4,898,305 $ - $ - Marketable securities as of September 30, 2022 $ 9,913,667 $ 9,913,667 $ - $ - Marketable securities as of December 31, 2021 $ - $ - $ - $ -
Net Loss per Common Share	Net Loss per Common Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. All vested outstanding options and warrants are considered potential common stock. The dilutive effect, if any, of stock options, warrants, and restricted stock units (“RSUs”) are calculated using the treasury stock method. All outstanding convertible notes are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, options, warrants, RSUs and convertible notes have been excluded from the Company’s computation of net loss per common share for the three and nine months ended September 30, 2022 and 2021. The following table summarizes the securities that were excluded from the diluted loss per share calculation: SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES Three Months Ended September 30, 2022 2021 Options 864,609 588,048 Warrants 4,739,723 3,704,997 Unvested RSUs 208,086 293,479 Convertible notes – common stock (1) - 697,582 Total 5,812,418 5,284,121 Nine Months Ended September 30, 2022 2021 Options 864,609 588,048 Warrants 4,739,723 3,704,997 Unvested RSUs 208,086 293,479 Convertible notes – common stock (1) - 697,582 Total 5,812,418 5,284,121 (1) As of September 30, 2021, all of the convertible notes had variable conversion prices and the shares issuable were estimated based on the market conditions. Pursuant to the note agreements, there were 12,876,004
Stock-based Compensation	Stock-based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation For stock options issued to employees and members of the board of directors for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. Pursuant to Accounting Standards Update (“ASU”) 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, the Company accounts for stock options issued to non-employees for their services in accordance with ASC 718. The Company uses valuation methods and assumptions to value the stock options that are consistent with the process for valuing employee stock options noted above.
Income Taxes	Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires the recognition of deferred income tax assets and liabilities related to the expected future tax consequences arising from temporary differences between the carrying amounts and tax bases of assets and liabilities based on enacted statutory tax rates applicable to the periods in which the temporary differences are expected to reverse. Any effects of changes in income tax rates or laws are included in income tax expense in the period of enactment. The Company records valuation allowances against deferred tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company routinely evaluates the realizability of deferred tax assets by assessing the likelihood that deferred tax assets will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, historical results are considered along with certain assumptions related to future earnings. As of September 30, 2022 and December 31, 2021, the Company had a full valuation allowance applied against its deferred tax assets. From time to time the Company may recognize an income tax benefit, in its consolidated statements of operations, related to uncertain tax positions taken. For uncertain tax positions that are “more likely than not” to sustain an income tax audit, the Company may record an allowance against certain deferred tax assets related to these positions. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the unaudited condensed consolidated statements of operations.
Research and Development Expenses	Research and Development Expenses Research and development expenses are expensed as incurred and recorded as a component of operating expenses in the Company’s condensed consolidated statements of operations.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUE RECURRING BASIS	The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2022, and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: SCHEDULE OF FAIR VALUE RECURRING BASIS Fair value measurements at reporting date using: Description Fair Value Quoted Significant other Significant Assets: Cash equivalents as of September 30, 2022 $ 4,898,305 $ 4,898,305 $ - $ - Marketable securities as of September 30, 2022 $ 9,913,667 $ 9,913,667 $ - $ - Marketable securities as of December 31, 2021 $ - $ - $ - $ -
SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES	The following table summarizes the securities that were excluded from the diluted loss per share calculation: SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES Three Months Ended September 30, 2022 2021 Options 864,609 588,048 Warrants 4,739,723 3,704,997 Unvested RSUs 208,086 293,479 Convertible notes – common stock (1) - 697,582 Total 5,812,418 5,284,121 Nine Months Ended September 30, 2022 2021 Options 864,609 588,048 Warrants 4,739,723 3,704,997 Unvested RSUs 208,086 293,479 Convertible notes – common stock (1) - 697,582 Total 5,812,418 5,284,121 (1) As of September 30, 2021, all of the convertible notes had variable conversion prices and the shares issuable were estimated based on the market conditions. Pursuant to the note agreements, there were 12,876,004

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS	SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS Patents and Licenses Accumulated Total Balance as of January 1, 2021 $ 3,676 $ 1,301,500 $ (640,908 ) $ 664,268 Amortization expense - - (74,528 ) (74,528 ) Balance as of December 31, 2021 3,676 1,301,500 (715,436 ) 589,740 Amortization expense - - (59,442 ) (59,442 ) Balance as of September 30, 2022 $ 3,676 $ 1,301,500 $ (774,878 ) $ 530,298 Weighted average remaining amortization period as of September 30, 2022 (in years) - 7.18
SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES	Accumulated amortization of intangible assets consists of the following: SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES Patents and Licenses Accumulated Balance as of January 1, 2021 $ 3,676 $ 637,232 $ 640,908 Amortization expense - 74,528 74,528 Balance as of December 31, 2021 3,676 711,760 715,436 Amortization expense - 59,442 59,442 Balance as of September 30, 2022 $ 3,676 $ 771,202 $ 774,878

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	Accrued expenses and other current liabilities consist of: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES September 30, December 31, Accrued payroll $ 26,250 $ 28,370 Accrued research and development expenses - 29,672 Accrued general and administrative expenses 88,397 76,928 Total accrued expenses $ 114,647 $ 134,970

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE ACTIVITY	A summary of the notes payable activity during the nine months ended September 30, 2022 is presented below: SCHEDULE OF NOTES PAYABLE ACTIVITY PPP Loan Outstanding, January 1, 2022 $ 250,000 Issuances - Forgiveness (250,000 ) Outstanding, September 30, 2022 $ -

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	A summary of the warrant activity during the nine months ended September 30, 2022, is presented below: SCHEDULE OF WARRANT ACTIVITY Weighted Average Number of Exercise Warrants Price Outstanding, January 1, 2022 4,739,871 $ 11.78 Granted - - Exercised - - Expired (148 ) 16,099.00 Outstanding, September 30, 2022 4,739,723 $ 10.89 Exercisable, September 30, 2022 4,739,723 $ 10.89
SCHEDULE OF STOCK OPTION ACTIVITY	A summary of the stock option activity during the nine months ended September 30, 2022 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY Weighted Average Number of Exercise Options Price Outstanding, January 1, 2022 839,639 $ 18.73 Granted 25,000 4.92 Forfeited (30 ) 3,273.00 Outstanding, September 30, 2022 864,609 $ 18.73 Exercisable, September 30, 2022 532,045 $ 17.50
SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS	A summary of the Company’s unvested RSUs as of September 30, 2022 is as follows: SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS Number of Shares Outstanding, January 1, 2022 293,480 Granted 24,876 Forfeited - Vested (110,270 ) Outstanding, September 30, 2022 208,086

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION	The following table presents net lease cost and other supplemental lease information: SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION Nine Months Nine Months Lease cost Operating lease cost (cost resulting from lease payments) $ 122,349 $ 118,779 Net lease cost $ 122,349 $ 118,779 Operating lease – operating cash flows (fixed payments) $ 122,349 $ 118,779 Operating lease – operating cash flows (liability reduction) $ 87,945 $ 74,749 Non-current leases – right of use assets $ 270,772 $ 386,816 Current liabilities – operating lease liabilities $ 134,031 $ 114,387 Non-current liabilities – operating lease liabilities $ 198,724 $ 332,755
SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES	Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of September 30, 2022: SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES Fiscal Year Operating Leases Remainder of 2022 $ 40,783 2023 168,028 2024 173,060 Total future minimum lease payments 381,871 Amount representing interest (49,116 ) Present value of net future minimum lease payments $ 332,755

NATURE OF THE ORGANIZATION, L_2

NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended						9 Months Ended
	Oct. 27, 2021	Sep. 30, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 10, 2021	Dec. 09, 2021	Nov. 09, 2021
Stockholders' equity, reverse stock split	1-for-4,000
Common stock, shares authorized		75,000,000	75,000,000						75,000,000		75,000,000	2,500,000	1,175,000
Underwritten public offerings														$ 23,000,000
Securities pursuant aggregate shares														2,300,000
Warrants to purchase shares of common stock														2,645,000
Net Income (Loss) Attributable to Parent		$ 4,655,825	$ 4,655,825	$ 4,675,241	$ 4,816,150	$ 4,184,232	$ 4,062,595	$ 15,653,330	$ 14,147,216	$ 23,900,157
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 9,600,000	$ 9,600,000						9,600,000
Net Cash Provided by (Used in) Operating Activities									$ 4,297,412	$ 2,184,894
Maximum [Member]
Common stock, shares authorized	300,000,000,000
Minimum [Member]
Common stock, shares authorized	75,000,000

SCHEDULE OF FAIR VALUE RECURRIN

SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Cash and cash equivalents, fair value disclosure	$ 4,898,305
Assets fair value disclosure	9,913,667
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash and cash equivalents, fair value disclosure	4,898,305
Assets fair value disclosure	9,913,667
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash and cash equivalents, fair value disclosure
Assets fair value disclosure
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash and cash equivalents, fair value disclosure
Assets fair value disclosure

SCHEDULE OF WEIGHTED AVERAGE DI

SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) - shares	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021		Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,812,418	5,284,121		5,812,418	5,284,121
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	864,609	588,048		864,609	588,048
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,739,723	3,704,997		4,739,723	3,704,997
Unvested RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	208,086	293,479		208,086	293,479
Convertible Notes Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		697,582	[1]		697,582	[1]
[1]As of September 30, 2021, all of the convertible notes had variable conversion prices and the shares issuable were estimated based on the market conditions. Pursuant to the note agreements, there were 12,876,004

SCHEDULE OF WEIGHTED AVERAGE _2

SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES (Details) (Parenthetical)	Sep. 30, 2021 shares
Accounting Policies [Abstract]
Common stock, capital shares reserved for future issuance	12,876,004

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Revenue	$ 29,000	$ 8,000	$ 116,100	$ 41,000
Cash Equivalents, at Carrying Value	$ 16,500,000		$ 16,500,000

SCHEDULE OF FINITE LIVED INTANG

SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Beginning Balance	$ 589,740	$ 664,268
Finite Lived Intangible Assets, Amortization expense	(59,442)	(74,528)
Finite Lived Intangible Assets, Ending Balance	530,298	589,740
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Beginning Balance	3,676	3,676
Finite Lived Intangible Assets, Accumulated Amortization, Beginning Balance	(3,676)	(3,676)
Finite Lived Intangible Assets, Amortization expense
Finite Lived Intangible Assets, Gross, Ending Balance	3,676	3,676
Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance	$ (3,676)	(3,676)
Finite Lived Intangible Assets, Weighted Average Amortization Period (in years)	0 years
License [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Beginning Balance	$ 1,301,500	1,301,500
Finite Lived Intangible Assets, Accumulated Amortization, Beginning Balance	(711,760)	(637,232)
Finite Lived Intangible Assets, Amortization expense	(59,442)	(74,528)
Finite Lived Intangible Assets, Gross, Ending Balance	1,301,500	1,301,500
Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance	$ (771,202)	(711,760)
Finite Lived Intangible Assets, Weighted Average Amortization Period (in years)	7 years 2 months 4 days
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Accumulated Amortization, Beginning Balance	$ (715,436)	(640,908)
Finite Lived Intangible Assets, Amortization expense	(59,442)	(74,528)
Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance	$ (774,878)	$ (715,436)

SCHEDULE OF FINITE LIVED INTA_2

SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 59,442	$ 74,528
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	3,676	3,676
Amortization expense
Ending Balance	3,676	3,676
License [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	711,760	637,232
Amortization expense	59,442	74,528
Ending Balance	771,202	711,760
Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	715,436	640,908
Amortization expense	59,442	74,528
Ending Balance	$ 774,878	$ 715,436

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll	$ 26,250	$ 28,370
Accrued research and development expenses		29,672
Accrued general and administrative expenses	88,397	76,928
Total accrued expenses	$ 114,647	$ 134,970

SCHEDULE OF NOTES PAYABLE ACTIV

SCHEDULE OF NOTES PAYABLE ACTIVITY (Details) - PPP loan [Member]	9 Months Ended
	Sep. 30, 2022 USD ($)
Short-Term Debt [Line Items]
Loans payable outstanding beginning	$ 250,000
Issuances
Forgiveness	(250,000)
Loans payable outstanding ending

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - Paycheck Protection Program [Member]	Mar. 14, 2021 USD ($)
Short-Term Debt [Line Items]
Notes payable	$ 250,000
Debt instrument, interest rate, stated percentage	1%
Debt instrument, maturity date	Mar. 14, 2026
Debt instrument, description	Pursuant to the note, principal and interest payments were deferred for ten months. At that time the Company was able to apply for loan forgiveness. At December 31, 2021, $250,000 was outstanding. On January 5, 2022, the total amount of the PPP loan was forgiven
Debt instrument, face amount	$ 250,000

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of warrants outstanding, beginning balance | shares	4,739,871
Weighted average exercise price, beginning balance | $ / shares	$ 11.78
Number of warrants outstanding, granted | shares
Weighted average exercise price, granted | $ / shares
Number of warrants outstanding, exercised | shares
Weighted average exercise price, exercised | $ / shares
Number of warrants outstanding, expired | shares	(148)
Weighted average exercise price, expired | $ / shares	$ 16,099
Number of warrants outstanding, ending balance | shares	4,739,723
Weighted average exercise price, ending balance | $ / shares	$ 10.89
Number of warrants outstanding, exercisable | shares	4,739,723
Weighted average exercise price, exercisable | $ / shares	$ 10.89

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Number of options, beginning balance	839,639
Weighted average exercise price, beginning balance	$ 18.73
Number of options, granted	25,000	586,959
Weighted average exercise price, granted	$ 4.92
Number of options, forfeited	(30)
Weighted average exercise price, forfeited	$ 3,273
Number of options, ending	864,609
Weighted average exercise price, ending	$ 18.73
Number of options, exercisable	532,045
Weighted average exercise price, exercisable	$ 17.50

SCHEDULE OF UNVESTED RESTRICTED

SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares outstanding beginning	293,480
Number of shares granted	24,876
Number of shares forfeited
Number of shares vested	(110,270)
Number of shares outstanding ending	208,086

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 25, 2022	Sep. 15, 2022	Mar. 18, 2021	Oct. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 10, 2021	Dec. 09, 2021	Nov. 08, 2021	Oct. 27, 2021
Class of Stock [Line Items]
Preferred stock, par value					$ 0.01		$ 0.01		$ 0.01
Common Stock, Shares Authorized					75,000,000		75,000,000		75,000,000	2,500,000	1,175,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period		838,549
[custom:DescriptionOfStockOptopnHeldByOfficerAndDirector]		(i) Lance Alstodt, the Company’s President, Chief Executive Officer and Chairman of the Board: 335,538 shares, (ii) Francisco Silva, the Company’s Vice President of Research and Development and a director: 335,538 shares; (iii) Robert Kristal, the Company’s Chief Financial Officer: 10,490 shares; (iv) Robert Paccasassi, the Company’s Vice President of Quality Assurance and Regulatory Compliance: 8,277 shares; (v) Nickolay Kukekov, one of the Company’s directors: 25,236 shares; (vi) Patrick F. Williams, one of the Company’s directors: 10,490 shares; and (vii) David Rosa, one of the Company’s directors: 10,490 shares
Number of options granted to purchase common stock							25,000	586,959
Share based compensation					$ 1,900	$ 1,700	$ 6,000	$ 17,400
Stock option granted date fair value							$ 4.88	$ 47.25
Unamortized compensation expense					90	3,200	$ 90	$ 3,200
Allocated share based compensation expense					3,100	2,900	9,600	19,900
Unrecognized compensation expense					10,800		$ 10,800
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of restricted stock units granted							24,876
Restricted stock units, vested							110,270
Allocated share based compensation expense					$ 1,200	$ 1,200	$ 3,600	$ 2,500
Restricted Stock Units (RSUs) [Member] | Two Employment Agreements [Member] | Chief Executive Officer and Chairman of the Board and Vice President [Member]
Class of Stock [Line Items]
Number of restricted stock units granted			24,876
Fair value granted for restricted stock			$ 4.21
Maximum [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized													300,000,000,000
Minimum [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized													75,000,000
2021 Stock Incentive Plan [Member]
Class of Stock [Line Items]
Number of shares of common stock authorized			1,175,000
Number of shares remain available for future grant					0		0
Two Thousand And Twenty One Plan [Member]
Class of Stock [Line Items]
Number of options granted to purchase common stock							864,609
Two Thousand And Twenty One Plan [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Number of options granted to purchase common stock							318,356
Share-based compensation,shares authorized							2,500,000
Share-based compensation,option exercise price per share					$ 5.08		$ 5.08
Beneficial Ownership [Member]
Class of Stock [Line Items]
Ownership percentage					9.99%		9.99%
Common Stock [Member]
Class of Stock [Line Items]
Debt instrument conversion price per share					$ 10		$ 10
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share Price		$ 13.50
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share Price		$ 5.08
Subsequent Event [Member]
Class of Stock [Line Items]
Restricted stock units, vested				2,074
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued												1,543,458
Preferred stock, par value												$ 0.01
Preferred stock, liquidation preference												$ 0.001
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued					1,543,158		1,543,158
Preferred stock voting rights							The terms of the Series B are substantially identical to those of the Series A, except that, among other things, the limitation on beneficial ownership of common stock of the Company upon a conversion of the Series B into Common Stock, and the limitation on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as provided for the Series A
Preferred stock voting percentage							9.99%
Series B Preferred Stock [Member] | Beneficial Ownership [Member]
Class of Stock [Line Items]
Ownership percentage					9.50%		9.50%
Common Class B [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued	25,000
Debt instrument conversion price per share	$ 10
Conversion of stock shares	1,518,158
Common Class B [Member] | Subsequent Event [Member] | Auctus Fund LLC [Member]
Class of Stock [Line Items]
Debt conversion, converted instrument, shares issued	25,000

COMMITMENTS (Details Narrative)

COMMITMENTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense	$ 989,170	$ 237,410	$ 2,839,731	$ 563,562
Clinical Services Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense	600,000		1,700,000
Prepaid expense	$ 300,000		$ 300,000
Clinical Services Agreement [Member] | Professional Research Consulting Inc [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Services agreement term					46 months
Research and development expense					$ 5,844,380
Prepaid expense					$ 328,152

SCHEDULE OF NET LEASE COST AND

SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Leases
Operating lease cost (cost resulting from lease payments)	$ 122,349	$ 118,779
Net lease cost	122,349	118,779
Operating lease – operating cash flows (fixed payments)	122,349	118,779
Operating lease – operating cash flows (liability reduction)	87,945	74,749
Non-current leases - right of use assets	270,772	386,816	$ 357,805
Current liabilities - operating lease liabilities	134,031	114,387	119,055
Non-current liabilities - operating lease liabilities	$ 198,724	$ 332,755	$ 301,645

SCHEDULE OF FUTURE MINIMUM PAYM

SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES (Details)	Sep. 30, 2022 USD ($)
Leases
Remainder of 2022	$ 40,783
2023	168,028
2024	173,060
Total future minimum lease payments	381,871
Amount representing interest	(49,116)
Present value of net future minimum lease payments	$ 332,755

LEASES (Details Narrative)

LEASES (Details Narrative) - Melville Lease [Member]		9 Months Ended
	Jan. 02, 2020 USD ($)	Sep. 30, 2022 ft²
Area of land | ft²		6,800
Lease description		The Melville Lease is scheduled to expire in December 2024 and provides for an annual base rental during the term, which commenced as of January 1, 2020, ranging between $153,748 and $173,060. The remaining term of this lease is approximately 2.25 years as of September 30, 2022
Remaining Lease Term		2 years 3 months
Weighted average incremental borrowing rate		12%
Minimum [Member]
Payments for rent	$ 153,748
Maximum [Member]
Payments for rent	$ 173,060